Index Options
CME Group
Nasdaq
Cboe
TradingView
Wall Street JournalBased on the provided financial report articles, I generated the title for the article: "VYST: Vystar Corporation's Quarterly Report for Q1 2024" Please note that the title may not be exact, as the provided text does not contain a clear title. However, based on the content and the company's name, I inferred the title to be related to Vystar Corporation's quarterly report for the first quarter of 2024.
Based on the provided financial report articles, I generated the title for the article: "VYST: Vystar Corporation's Quarterly Report for Q1 2024" Please note that the title may not be exact, as the provided text does not contain a clear title. However, based on the content and the company's name, I inferred the title to be related to Vystar Corporation's quarterly report for the first quarter of 2024.
The financial report presents the financial statements of the company for the quarter ended March 31, 2024. The company reported a net income of $X million, with total revenues of $Y million and total expenses of $Z million. The company’s balance sheet shows total assets of $W million, total liabilities of $V million, and total stockholders’ equity of $U million. The company’s cash and cash equivalents increased by $X million during the quarter, and its accounts receivable and payable decreased by $Y million and $Z million, respectively. The company’s operating cash flow was $X million, and its investing and financing activities resulted in a net outflow of $Y million. The company’s debt-to-equity ratio was X:Y, and its interest coverage ratio was Z:W.
OVERVIEW
This analysis provides an overview of RxAir’s financial performance and outlook. RxAir is a company that promotes healthy lifestyles through its innovative air purification technology. The company’s key product lines include the RxAir Residential Filterless Air Purifier, RX400 and RX800 FDA-cleared Class II Filterless Air Purifiers, and the RX3000 Commercial FDA-cleared Class II Air Purifier.
In addition to its air purification business, Vystar also produces Vytex, a multi-patented latex raw material with reduced allergy-causing proteins. Vytex has been commercially available for 14 years and is used by various manufacturers in products like electrical gloves, condoms, and adhesives.
The company is also exploring new opportunities by combining its UV-C technology with Fluid Energy’s ultrasonic technology to improve air and water purification products.
RESULTS OF OPERATIONS
Comparison of the Three Months Ended March 31, 2024 with the Three Months Ended March 31, 2023
| Metric | Q1 2024 | Q1 2023 | $ Change | % Change |
|---|---|---|---|---|
| Revenue | $37,607 | $409,907 | $(372,300) | -90.8% |
| Cost of Revenue | $17,420 | $76,698 | $(59,278) | -77.3% |
| Gross Profit | $20,187 | $333,209 | $(313,022) | -93.9% |
| Total Operating Expenses | $357,425 | $383,926 | $(26,501) | -6.9% |
| Loss from Operations | $(337,238) | $(50,717) | $(286,521) | 564.9% |
| Net Loss | $(374,718) | $(1,277,076) | $902,358 | -70.7% |
Revenues Revenues decreased by 90.8% in Q1 2024 compared to Q1 2023, primarily due to the company’s internal reorganization and focus on its core RxAir and Vytex product lines.
Gross Profit Gross profit decreased by 93.9% in Q1 2024 compared to Q1 2023, consistent with the decrease in revenues.
Operating Expenses Operating expenses decreased by 6.9% in Q1 2024 compared to Q1 2023, mainly due to the reduced revenues.
Discontinued Operations Loss from discontinued operations decreased by 97.6% in Q1 2024 compared to Q1 2023, as the company completed the winding down of these operations.
Net Loss Net loss decreased by 70.7% in Q1 2024 compared to Q1 2023, primarily due to the significant reduction in loss from discontinued operations.
LIQUIDITY AND CAPITAL RESOURCES
The company has incurred significant losses and experienced negative cash flow since inception. As of March 31, 2024, the company had $11,768 in cash and a deficit in working capital of approximately $6 million. The accumulated deficit amounted to approximately $61 million.
Management plans to finance future operations using cash on hand, increased revenue from RxAir and Vytex, and capital raised through common stock subscriptions. However, there are no assurances that the company will be able to achieve projected revenue levels or obtain additional financing, which could have a material adverse effect on its ability to continue as a going concern.
DISCLOSURE REGARDING FORWARD-LOOKING STATEMENTS
The company’s Management’s Discussion and Analysis contains forward-looking statements that are subject to various risks and uncertainties, including international and national economic conditions, product development and acceptance, regulatory changes, competition, and the company’s ability to attract and retain qualified personnel and protect its technology. These forward-looking statements reflect the company’s best judgment, but actual results may differ materially from those discussed due to the inherent uncertainties involved.